Finasteride is the most clinically studied medication for male pattern hair loss. YourMD partners compound topical formulations and combinations not commercially available — including the gold-standard fin/minoxidil combo and 3-in-1 fin/minoxidil/tretinoin solutions.
Male pattern hair loss (androgenetic alopecia) is driven by dihydrotestosterone (DHT), which causes genetically susceptible hair follicles to miniaturize over time. Finasteride blocks the enzyme 5-alpha reductase, reducing scalp DHT levels by approximately 60–70% at standard oral doses.
Commercial finasteride is available as an oral 1 mg tablet (Propecia® or generic). Compounding adds topical formulations that deliver medication directly to the scalp with substantially reduced systemic absorption.
A 2025 systematic review and meta-analysis of seven randomized controlled trials found that the combination of topical finasteride with topical minoxidil produced superior improvements in hair density and hair diameter compared to either treatment alone. A 502-patient retrospective study reported that 92.4% of men on combination therapy achieved stable or improved hair outcomes at 12 months. This is considered the gold-standard medical regimen for androgenetic alopecia.
Oral finasteride: 2–4% report decreased libido, erectile dysfunction, or decreased ejaculate volume. Effects are typically reversible upon discontinuation, though rare persistent post-finasteride syndrome has been reported.
Topical finasteride: similar potential side effects but lower incidence due to reduced systemic absorption. Scalp irritation is possible.
Contraindications: pregnancy or women who may become pregnant (finasteride is teratogenic to male fetuses). Do not handle broken tablets.
Medical disclaimer: Educational content, not medical advice. Page medically reviewed by Teja V. Surapaneni, MD, MS — Board-Certified Internal Medicine (NV, WA, OR, WY). Last reviewed: April 17, 2026